New approaches to drug safety: A pharmacovigilance tool kit

Nature Reviews Drug Discovery

Volumn 8, Issue 10, 2009, Pages 779-782

  Wise, Lesley ^a   Parkinson, John ^a   Raine, June ^a   Breckenridge, Alasdair ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BOSENTAN; CYCLOSPORIN; ETANERCEPT; IBUPROFEN; IDURONATE 2 SULFATASE; INFLIXIMAB; NATALIZUMAB; ORAL ANTIDIABETIC AGENT; PARACETAMOL; VARENICLINE; WART VIRUS VACCINE;

ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL; DATA COLLECTION METHOD; DRUG EXPOSURE; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTER SYNDROME; MEDICAL RECORD; MENTAL DISEASE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT INFORMATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PULMONARY HYPERTENSION; REFERENCE DATABASE; REGISTER; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; THERAPY EFFECT; VERRUCA VULGARIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 70349652456     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3002     Document Type: Article

References (15)

1. Evans, S. in Pharmacovigilance 2nd edn Ch. 19 (eds Mann, R. & Andrews, E.) 249-255 (John Wiley, Chichester, 2007).
2. Medicines and Healthcare products Regulatory Agency. Drug Safety Update: Volume 1, Issue 12 [online] (2008).
3. Ransohoff, R. M. et al. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356, 2622-2629 (2007).
4. Silman, A., Symmonds, D., Scott, D. G. I. & Griffiths, I. British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 62, S28 (2003).
5. Morrow, J. et al. Malformation risks of antiepileptiform drugs in pregnancy: A prospective study from the UK Epilepsy and Pregnancy Register. J. Neurol. Neurosurg. Psychiatr. 77, 193-198 (2006).
6. del Toro-Riera, M. et al. Follow up of patients with Hunter syndrome: The Hunter Outcome Survey (HOS) registry. Rev. Neurol. 44, S513-S517 (2007).
7. Biederbeck-Noll, A. B. et al. Verapamil is associated with an increased risk of cancer in the elderly: The Rotterdam study. Eur. J. Cancer. 39, 98-105 (2003).
8. Harrison-Woolrych, M. et al. Safety and usage of atypical antipsychotic medicines in children: A nationwide prospective cohort study. Drug Safety 7, 569-573 (2007).
9. Lesko, S. M. and Mitchell, A. A. The safety of acetaminophen and ibuprofen among children younger than two years old. Paediatrics 104, 39-51 (1999).
10. Friis-Moller, N. et al. Combination antiretroviral therapy and the risk of myocardial infarction. N. Engl. J. Med. 349, 1993-2003 (2003).
11. Segal, E. S. et al. Risk management strategies in the postmarketing period: Safety experience with the US and European bosentan surveillance programmes. Drug Safety 28, 971-980 (2005).
12. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-570 (2008).
13. Hughes, D. A., Bayoumi, A. M. & Pirmohamed, M. Current assessment of risk-benefit by regulators: Is it time to introduce decision analyses? Clin. Pharmacol. Ther. 82, 123-127 (2007).
14. van Staa. T. P., Smeeth, L., Persson, I., Parkinson, J. & Leufkens, H. G. What is the harm-benefit ratio of Cox-2 inhibitors? Int. J. Epidemiol. 37, 405-413 (2008).
15. van Staa, T. P., Barlow, D., Cooper, C. & Leufkens, H. G. M. Individualising risks and benefits of hormone therapy. Menopause 15, 374-381 (2008).